AURA — Aura Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1501796 ·
Last close
$7.01
Market Cap
$725.09M
52W High
$9.53
52W Low
$6.03
ADV30
589,873
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -34,866,000 | -33,685,000 | 137,677,000 | 84,793,000 | 30,430,000 |
| Dec 2025 | 0 | — | -27,237,000 | -25,559,000 | 169,430,000 | 59,515,000 | 32,517,000 |
| Sep 2025 | 0 | — | -27,906,000 | -26,130,000 | 190,024,000 | 47,553,000 | 33,357,000 |
| Jun 2025 | 0 | — | -28,613,000 | -27,019,000 | 204,397,000 | 107,367,000 | 29,768,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,280,000
Investing CF
$60,680,000
Financing CF
$77,359,000
CapEx
$-362,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.92
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-480,418,000
Inventory
—
Receivables
—
ST Investments
$84,726,000
EBIT TTM
$-112,791,000
Pretax Income TTM
$-106,084,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -112,791,000 | -106,191,000 | 169,430,000 | 32,517,000 | — | -84,742,000 |
| Dec 2024 | 0 | -96,116,000 | -86,919,000 | 182,503,000 | 30,533,000 | — | -79,805,000 |
| Dec 2023 | 0 | -84,991,000 | -76,408,000 | 255,075,000 | 29,227,000 | — | -63,847,000 |
| Dec 2022 | 0 | -60,295,000 | -58,763,000 | 223,935,000 | 28,352,000 | — | -54,601,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.03
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $733.44M | $10.01 | — |
| SLDB | Solid Biosciences Inc. | $793.50M | $8.06 | — |
| DBVT | DBV Technologies S.A. | $799.04M | $13.50 | — |
| ALLO | Allogene Therapeutics, Inc. | $648.89M | $1.88 | — |
| AGMB | Agomab Therapeutics NV | $633.82M | $12.87 | — |
News headlines (Yahoo Finance, 1h cache)
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
2026-07-08 11:01 · Yahoo
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
2026-06-01 12:00 · Yahoo
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
2026-05-27 20:04 · Yahoo
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
2026-05-20 02:02 · Yahoo
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-19 20:50 · Yahoo
Aura Biosciences to Participate in Upcoming Investor Conferences
2026-05-12 20:01 · Yahoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-11 20:01 · Yahoo
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-05 21:15 · Yahoo
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
2026-05-04 13:03 · Yahoo
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-05-04 10:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.